Lilly unites caring with discovery to create medicines that make life better for people around the world. Over 47 million people count on Lilly medicines each year. In the nearly 150 years we’ve been in business, we’ve developed and delivered trusted medicines that help people get better, feel better and live better.
Inclusive representation in clinical trials is critical – it helps our researchers ensure that we’re making medicines that will be as effective as possible for patients who use them.
Lilly’s partnership with BlackDoctor.org aims to educate and encourage clinical trial participation and awareness.
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants with Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
-
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
-
Participants 6 Months to
